| Recruiting | Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH NCT07187193 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib NCT06582745 | Cook Children's Health Care System | Phase 2 |
| Recruiting | To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recu NCT05997602 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Phase 2 |
| Unknown | Safety and Efficacy of CD207 Targeted CAR-T Cell Therapy in Patients With R/R Langerhans Cell Histiocytosis NCT05477446 | Beijing Friendship Hospital | Phase 1 |
| Recruiting | Histiocytic Disorder Follow-up Study NCT05915208 | University of Alabama at Birmingham | — |
| Unknown | The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (EC NCT05092815 | Shanghai Henlius Biotech | Phase 2 |
| Unknown | LCH in Adults: a Collaborative, Prospective-retrospective, Observational Study NCT04627090 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Unknown | Thalidomide, Cyclophosphamide and Dexamethasone for Recurrent/Refractory Adult Langerhans Cell Histiocytosis NCT04120519 | Peking Union Medical College Hospital | Phase 2 |
| Unknown | AraC for Newly Diagnosed Adult Langerhans Cell Histiocytosis NCT04121819 | Peking Union Medical College Hospital | Phase 2 |
| Recruiting | A Prospective Study for the Treatment of Children With Newly Diagnosed LCH Using a Cytarabine Contained Protoc NCT04773366 | Shanghai Children's Medical Center | Phase 3 |
| Unknown | A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutati NCT03585686 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 2 |
| Completed | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03220035 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients W NCT03096782 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Denosumab for the Treatment of Adult LCH NCT03270020 | Hellenic Society for the Study of Bone Metabolism | Phase 2 |
| Active Not Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanc NCT03155620 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histi NCT02205762 | North American Consortium for Histiocytosis | Phase 2 / Phase 3 |
| Recruiting | Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH) NCT02670707 | Baylor College of Medicine | Phase 3 |
| Completed | Evaluation of Exercise Capacity and Exercise Limitation in Patients With Pulmonary Langerhans Cell Histiocytos NCT02665546 | InCor Heart Institute | — |
| Completed | Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement NCT02608619 | Memorial Sloan Kettering Cancer Center | — |
| Active Not Recruiting | Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Di NCT02425904 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | Methotrexate and Cytosine in Adult Langerhans Cell Histiocytosis NCT02389400 | Peking Union Medical College Hospital | Phase 2 |
| Completed | A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis NCT01395004 | GlaxoSmithKline | Phase 2 |
| Unknown | Central China Rosai-Dorfman Disease Registry NCT05284942 | Tongji Hospital | Phase 4 |
| Completed | Stem Cell Transplant for Immunologic or Histiocytic Disorders NCT00176865 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Terminated | T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders NCT00176826 | Masonic Cancer Center, University of Minnesota | Phase 2 / Phase 3 |
| Completed | Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH NCT00588536 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Withdrawn | Clofarabine for Langerhans in Pedi NCT01796405 | Dana-Farber Cancer Institute | Phase 2 |